000166537 001__ 166537
000166537 005__ 20240229133523.0
000166537 0247_ $$2doi$$a10.1016/j.ijrobp.2020.12.005
000166537 0247_ $$2pmid$$apmid:33321192
000166537 0247_ $$2ISSN$$a0360-3016
000166537 0247_ $$2ISSN$$a1879-355X
000166537 0247_ $$2altmetric$$aaltmetric:95868861
000166537 037__ $$aDKFZ-2020-02980
000166537 041__ $$aeng
000166537 082__ $$a610
000166537 1001_ $$0P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aHörner-Rieber, Juliane$$b0$$udkfz
000166537 245__ $$aIntensity-modulated radiotherapy (IMRT) with simultaneously integrated boost shortens treatment time and is non-inferior to conventional radiotherapy followed by sequential boost in adjuvant breast cancer treatment: results of a large randomized phase III trial (IMRT-MC2 trial).
000166537 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2021
000166537 3367_ $$2DRIVER$$aarticle
000166537 3367_ $$2DataCite$$aOutput Types/Journal article
000166537 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1617961164_3293
000166537 3367_ $$2BibTeX$$aARTICLE
000166537 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000166537 3367_ $$00$$2EndNote$$aJournal Article
000166537 500__ $$a#EA:E050#LA:E050#2021 Apr 1;109(5):1311-1324
000166537 520__ $$aIn the modern era, improvements in radiotherapy techniques have paved the way for simultaneous integrated boost irradiation in adjuvant breast radiotherapy following breast conservation surgery (BCS). Nevertheless, randomized trials supporting the non-inferiority of this treatment to historical standards of care approach are lacking.A prospective, multicenter, randomized phase-III-trial (XXX) was performed to analyze non-inferiority of conventional fractionated intensity-modulated radiotherapy with simultaneous integrated boost (IMRT-SIB) to 3-D-conformal radiotherapy with sequential boost (3-D-CRT-seqB) for breast cancer patients. Primary outcomes were local control (LC) rates at 2 and 5 years (non-inferiority margin at hazard ratio of 3.5) as well as cosmetic results 6 weeks and 2 years post radiotherapy (evaluated via photo documentation calculating the relative breast retraction assessment (pBRA) score (non-inferiority margin of 1.25)).A total of 502 patients were randomly assigned from 2011 to 2015. After a median follow-up of 5.1 years, the 2-year LC for the IMRT-SIB arm was non-inferior to the 3-D-CRT-seqB arm (99.6% vs. 99.6%, respectively; HR 0.602, 95%-CI: [0.123-2.452], p=0.487). In addition, non-inferiority was also demonstrated for cosmesis following IMRT-SIB and 3-D-CR-seqB at both 6 weeks (median pBRA 9.1% versus 9.1%) and 2 years (median pBRA 10.4% versus 9.8%) post radiotherapy (95%-CI [-0.317; 0.107] %/year, p=0.332). Cosmetic assessment according to the Harvard scale by both the patient and the treating physician as well as late toxicity evaluation with the LENT-SOMA criteria revealed no significant differences between treatment arms. Finally, there was no difference in overall survival rates (99.6% versus 99.6%; HR 3.281, 95%-CI: [-0.748-22.585], p=0.148) for IMRT-SIB and 3-D-CRT-seqB, respectively.This is the first prospective trial reporting the non-inferiority of IMRT-SIB versus 3-D-CRT-seqB with respect to cosmesis and LC at 2 years of follow up. This treatment regimen considerably shortens adjuvant radiotherapy times without compromising clinical outcomes.
000166537 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000166537 588__ $$aDataset connected to CrossRef, PubMed,
000166537 650_7 $$2Other$$a3-D-conformal radiotherapy
000166537 650_7 $$2Other$$aBreast cancer
000166537 650_7 $$2Other$$acosmesis
000166537 650_7 $$2Other$$aintensity-modulated radiotherapy (IMRT)
000166537 650_7 $$2Other$$asequential boost irradiation
000166537 650_7 $$2Other$$asimultaneous integrated boost (SIB)
000166537 7001_ $$aForster, T.$$b1
000166537 7001_ $$aHommertgen, A.$$b2
000166537 7001_ $$aHaefner, M. F.$$b3
000166537 7001_ $$aArians, N.$$b4
000166537 7001_ $$aKönig, L.$$b5
000166537 7001_ $$aHarrabi, S. B.$$b6
000166537 7001_ $$aSchlampp, I.$$b7
000166537 7001_ $$aWeykamp, F.$$b8
000166537 7001_ $$aLischalk, J. W.$$b9
000166537 7001_ $$aHeinrich, V.$$b10
000166537 7001_ $$aWeidner, N.$$b11
000166537 7001_ $$aHüsing, J.$$b12
000166537 7001_ $$aSohn, C.$$b13
000166537 7001_ $$aHeil, J.$$b14
000166537 7001_ $$aHof, H.$$b15
000166537 7001_ $$aKrug, D.$$b16
000166537 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b17$$udkfz
000166537 773__ $$0PERI:(DE-600)1500486-7$$a10.1016/j.ijrobp.2020.12.005$$gp. S0360301620346514$$n5$$p1311-1324$$tInternational journal of radiation oncology, biology, physics$$v109$$x0360-3016$$y2021
000166537 909CO $$ooai:inrepo02.dkfz.de:166537$$pVDB
000166537 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000166537 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000166537 9130_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000166537 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000166537 9141_ $$y2021
000166537 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-09-02$$wger
000166537 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-02
000166537 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-02
000166537 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-02
000166537 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-02
000166537 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-09-02
000166537 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-09-02
000166537 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-09-02
000166537 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-02
000166537 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-02
000166537 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J RADIAT ONCOL : 2018$$d2020-09-02
000166537 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-09-02
000166537 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-09-02
000166537 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J RADIAT ONCOL : 2018$$d2020-09-02
000166537 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000166537 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000166537 980__ $$ajournal
000166537 980__ $$aVDB
000166537 980__ $$aI:(DE-He78)E050-20160331
000166537 980__ $$aI:(DE-He78)HD01-20160331
000166537 980__ $$aUNRESTRICTED